Loading clinical trials...
Loading clinical trials...
The Effect of the Co-administration of Atazanavir (ATV) and Ritonavir (RTV) on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects
Conditions
Interventions
Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)
Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Locations
1
United States
Covance Cpu, Inc
San Diego, California, United States
Start Date
July 1, 2006
Primary Completion Date
November 1, 2006
Completion Date
November 1, 2006
Last Updated
April 8, 2011
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT05897099
NCT06665646
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions